The vascular microenvironment has been extensively studied in sarcomas and osteosarcoma (OS), revealing that the expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 correlates with poor outcomes in OS patients. This evidence concerns the gene VEGFA and sarcoma.